Please use this identifier to cite or link to this item:
Title: Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients.
Austin Authors: Mithraprabhu, Sridurga;Morley, Rachel;Khong, Tiffany;Kalff, Anna;Bergin, Krystal;Hocking, Jay;Savvidou, Ioanna;Bowen, Kathryn M;Ramachandran, Malarmathy;Choi, Kawa;Wong, Boris Ka Leong;Reynolds, John;Spencer, Andrew
Affiliation: Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
Department of Clinical Hematology, Monash University, Clayton, Victoria, Australia
Epidemiology and Preventive Medicine, Alfred Health-Monash University, Clayton, Victoria, Australia
Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria, Australia
Malignant Hematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia
Haematology, Box Hill Hospital, Melbourne, Victoria, Australia
Issue Date: 16-Apr-2019 2019-04-16
Publication information: Leukemia 2019; online first: 16 April
Abstract: Monitoring tumour burden and therapeutic response through analyses of circulating cell-free tumour DNA (ctDNA) and extracellular RNA (exRNA) in multiple myeloma (MM) patients were performed in a Phase Ib trial of 24 relapsed/refractory patients receiving oral azacitidine in combination with lenalidomide and dexamethasone. Mutational characterisation of paired BM and PL samples at study entry identified that patients with a higher number of mutations or a higher mutational fractional abundance in PL had significantly shorter overall survival (OS) (p = 0.005 and p = 0.018, respectively). A decrease in ctDNA levels at day 5 of cycle 1 of treatment (C1D5) correlated with superior progression-free survival (PFS) (p = 0.017). Evaluation of exRNA transcripts of candidate biomarkers indicated that high CRBN levels coupled with low levels of SPARC at baseline were associated with shorter OS (p = 0.000003). IKZF1 fold-change <0.05 at C1D5 was associated with shorter PFS (p = 0.0051) and OS (p = 0.0001). Furthermore, patients with high baseline CRBN coupled with low fold-change at C1D5 were at the highest risk of progression (p = 0.0001). In conclusion, this exploratory analysis has provided the first demonstration in MM of ctDNA for predicting disease outcome and of the utility of exRNA as a biomarker of therapeutic response.
DOI: 10.1038/s41375-019-0469-x
ORCID: 0000-0002-8825-8625
PubMed URL: 30992504
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.